Spatially fractionated radiation therapy (GRID) with megavoltage x-ray beam is typically used to treat large and bulky malignant tumors. Currently most of the GRID treatment is performed by using the linear accelerator with either the multileaf collimator or with the commercially available block. A novel method to perform GRID treatments using Helical Tomotherapy ( HT) was developed at the Radiation Oncology Department, College of Medicine, the University of Arkansas for Medical Sciences. In this study, we performed a dosimetric comparison of two techniques of GRID therapy: one on linear accelerator with a commercially available GRID block (LINAC-GRID) as planned on the Pinnacle planning station (P-TPS); and helical tomotherapy-based GRID (HT-GRID) technique using a novel virtual TOMOGRID template planned on Tomotherapy treatment planning station (HT-TPS). Three dosimetric parameters: gross target volume (GTV) dose distribution, GTV target dose inhomogeneity, and doses to regions of interest were compared. The comparison results show that HT-GRID dose distributions are comparable to those of LINAC-GRID for GTV coverage. Doses to the majority of organs-at-risk (OAR) are lower in HT-GRID as compared to LINAC-GRID. The maximum dose to the normal tissue is reduced by 120% for HT-GRID as compared to the LINAC-GRID. This study indicate that HT-GRID can be used to deliver spatially fractionated dose distributions while allowing 3-D optimization of dose to achieve superior sparing of OARs and
Introduction
Spatially fractionated radiation therapy (GRID) has been used successfully as a part of a palliative or curative treatment of massive or bulky malignant tumor by irradiating the target through a special grid collimator. GRID therapy allows a high dose of radiation to be delivered in a single session by irradiating a given volume through isolated small openings simulating interstitial brachytherapy dose distribution.
Historically, GRID therapy was used to overcome the skin toxicity from orthovoltage beams when treating deep tumors. Skin toxicities were the limiting factor in the orthovoltage radiotherapy era. By using a GRID technique, the skin under the blocked areas of the GRID pattern was spared allowing adequate skin healing while simultaneously results in adequate dose to deep tumor volumes. With the advent of the modern megavoltage energy linear accelerator with skin sparing capabilities, the use of GRID technique gradually disappeared. The GRID technique using megavoltage X-ray was started in the late 1980s (1, 2) as a palliative treatment of bulky tumors. Currently GRID therapy is performed either by using a commercially available GRID block (3, 4) or multileaf collimator (MLC) (5) of a linear accelerator. Typically a large single dose of 15 Gy or higher is delivered to the maximum dose using single radiation field. GRID field definition is critical in order to avoid delivering large single dose of radiation to the OARs. GRID therapy of deep-seated tumors still remains a challenging clinical problem due to the physical limitations of linear accelerator-based GRID therapy (LINAC-GRID). A current limitation of LINAC-GRID is the limited ability to shape the 3-D dose distribution with potential spillage of maximum dose outside of the intended target and inability to adequately spare OARs.
The purpose of this study was to perform a dosimetric comparison of GRID therapy between a LINAC-GRID and a novel virtual HT-GRID. The implications and potential for treating deep-seated tumors with complex geometry will be discussed.
Materials and Methods

GRID Block Design and Dosimetric Characteristics of LINAC-GRID
The commercially available GRID block used for 2100 EX Varian linear accelerator is manufactured by Radiation Products Design, Inc. (Albertive, MN). This block is constructed by casting a hexagonal array of divergent openings of 14.3 mm in diameter with 21.1 mm center to center spacing projected in the plane of isocenter. The block is made of 7.5 centimeter Cerrobend alloy mounted on an accessory tray on the head of the linear accelerator ( Figure 1 ).
The dose profile of the GRID block was measured using the Kodak EDR2 films with solid water phantom at 100 cm SSD at D max , and at a depth of 10 cm for both the 6 MV and 18 MV X-ray beams. The EDR2 film calibration was performed by running an in-house step wedge calibration procedure. Film images were scanned by Epson perfection V700 red channel flatbed scanner and then the images were imported to an in-house program, ePin, for film analysis. ePin can read the film in red channel and then converted the image pixel values into optical density values. The heterogeneity of the dose distribution for GRID therapy is quantified by the valley to peak dose ratio, which is defined as the ratio of the minimum dose under a shielded area to the maximum dose under an exposed area (6) .
A solid water phantom was scanned as a phantom patient in the Philips Big Bore Brilliance CT Simulator. The obtained CT image data set was transferred to the Pinnacle v9.0 TPS for contouring and planning. A 1000 cc spherical GTV was generated and the commercially available GRID block was used for treatment planning. The GRID phantom treatment plan was generated using the same clinical approach as used for real GRID patients (7) . The prescription dose was 20 Gy to maximum point using 18 MV X-ray beams. The average dose to the GRID target and the heterogeneity of the dose distribution (valley to peak dose ratio) inside the GRID target were obtained.
TOMOGRID Template Design and Dosimetric Characteristics of HT-GRID
The virtual TOMOGRID templates used in Hi-Art Helical Tomotherapy system (Accuray, Inc., Madison, WI) were generated by the in-house software, DICOMan. It can generate the programmable virtual TOMOGRID template and can configure it in various settings of TOMOGRID targets and avoidance structures (Figures 2 and 3 ). The virtual TOMOGRID template can be beehive (openings are staggered) and regular shape (openings in straight rows and columns). Their cross-sectional shapes can be in one of four predefined shapes: circle, square, diamond, and hexagon. Figure 2 shows the virtual TOMOGRID template configuration module. The structure of avoidance can also be created by extracting TOMOGRID targets from GTV volume.
In this study, the virtual TOMOGRID template consists of three major elements: the GTV, the TOMOGRID target (the cylindrical structures mimicking openings of commercially available GRID blocks), and an avoidance structure created by extracting the TOMOGRID target from the GTV. The avoidance structure is used to aid in conforming the dose to the actual TOMOGRID targets, thus creating a similar valley to peak dose distribution as seen in LINAC-GRID therapy. Figure 3 shows an example of the virtual TOMOGRID template generated by DIOCMan with 14 mm openings and the center to center distance of 22 mm.
The goal of the design of virtual TOMOGRID template is to produce peak-and-valley dose distribution similar to those obtained with the LINAC-GRID plan using commercially available GRID block. But the physical pattern of the TOMOGRID template may not exactly mimic the GRID block used with LINAC-GRID.
LINAC-GRID and TOMO-GRID use the same CT image dataset and same GTV volume. These dataset and GTV were transferred to the DICOMan software for creation of the structures required for virtual TOMOGRID template. HT treatment plans based on TOMOGRID targets and the avoidance structure were generated on the v4.0.4 HT-TPS. The prescription was set to 20 Gy to the maximum point of the TOMOGRID target using 6 MV X-ray beams. A treatment plan was generated using a field width of 1 cm, a pitch of 0.215, and a modulation factor of 2.5. These optimization parameters were chosen from clinical experience in treating non-GRID patients with HT. The capability of delivering the typical GRID therapy dose distribution using HT-GRID was validated using solid water phantom as a dummy patient. Various solid water phantom treatment plans corresponding to different designs of virtual TOMOGRID templates were generated.
The dose profiles were measured using Kodak EDR2 films at the isocenter plane and the heterogeneity of the dose distribution was also quantified by the valley to peak dose ratio. The results were compared with LINAC-GRID treatment plan.
Dosimetric Comparison of HT-GRID with Actual LINAC-GRID in Clinical Use
A patient with a deep-seated bulky tumor treated with LINAC-GRID in our facility was selected ( Figure 7A ). The patient CT images and the RT structures were sent to the DICO-Man software to generate the TOMOGRID template. All regions of interest (OARs, TOMOGRID targets, and avoidance structure) were transferred to the HT-TPS to generate a HT-GRID treatment plan. Various HT-GRID plans were generated corresponding to different virtual TOMOGRID templates. Then HT-GRID treatment plans were compared to the real patient's LINAC-GRID treatment plan concluding in the selection of two virtual TOMOGRID templates (template 1 and template 2) based on dose volume histogram (DVH) and the peak-and-valley dose distribution similarity between HT-and LINAC-GRID plans. These two HT-GRID plans have the following characteristics: the opening diameters of 13 mm and 16 mm; and the center-to-center distance between adjacent openings of 54 mm and 45 mm respectively. The heterogeneity of the dose distribution inside the GTV target for the patient was also calculated using the valley to peak dose ratio and compared to the LINAC-GRID plans.
Patient Delivered Dose Verification
Patient-specific quality assurance (QA) for HT treatment plan was performed by measuring treatment plan dose distributions as delivered dose to the PTW Octavius phantom and 729 2D ion chamber array (PTW, Freiburg, Germany), which has 729 ionization chambers in a 27 3 27 matrix covering an area of 27 cm 3 27 cm. The dose measurement results were analyzed by PTW-VeriSoft software. Gamma criteria of 3% of dose difference and up to 3 mm distance to agreement was used to evaluate the point dose test result and the field area passing test was measured by scoring the gamma agreement index (%). The absolute patient delivered dose was also verified by measuring the point dose at isocenter using a PTW ion chamber (PTW N31010, 0.125 cc) with the cylindrical solid water phantom provided by HT Company to cross-check the delivered patient dose.
Results
Beam Characteristics Using Solid Water Phantom for LINAC-GRID and HT-GRID
The depth dependence of the dose profiles at D max and at a depth of 10 cm was measured using solid water phantom with LINAC-GRID. The results show that for the opening area under the grid block, the dose decreases with increasing depth and the decrease was more pronounced for lower energy X-ray beams. But for the dose under the blocked area, the dose is nearly the same for both 6 MV and 18 MV X-ray beam ( Figure 4A , 4B for 6 MV beams and Figure 4C , 4D for 18 MV beams). The average valley to peak dose ratio was around 0.2 for 6 MV X-ray beams and 0.3 for 18 MV X-ray beams at D max . These results are in agreement with those reported by Meigooni et al. (3) .
With the HT-GRID and 6 MV X-ray, the dose profiles were also measured at isocenter plane using the solid water phantom. Figure 5A to Figure 5C are the dose profiles using virtual TOMOGRID template 1 and Figure  5D to 5F are the dose profiles using virtual TOMOGRID template 2. Figures 5 show similar patterns of dose distributions between HT-GRID and LINAC-GRID. The valley-to-peak dose ratios for the two selected TOMOGRID templates were 0.5 and 0.42 at isocenter positions. 
Dosimetric Comparison for Dummy Patient Using Solid Water Phantom
Dummy patient treatment plans were generated using solid water phantom using Pinnacle-TPS (P-TPS) and HT-TPS. These treatment plans have similar GTV DVH distributions. The isodose distributions calculated from P-TPS and HT-TPS are shown in Figure 6 (Figure 6A P-TPS and Figure  6B HT-TPS). The mean dose to the GTV target was 7.76 Gy calculated from the P-TPS and was 8.1 Gy calculated from HT-TPS. Figure 6 also shows that the maximum dose is located outside the GTV target for the P-TPS plan whereas the maximum dose is located inside the GTV target for the HT-TPS plan.
Dosimetric Comparison for Treated GRID Patient
A previously patient treated to a deep-seated bulky tumor using LINAC-GRID was selected for re-planning using HT-TPS. The isodose distribution of the GTV target from both treatment plans are shown in Figure 7 located outside the GTV target due to the irregular shape of the tumor. Furthermore, the maximum dose point is located outside the GTV target as well ( Figure 7A ). For the HT plans, the cylindrical dose distribution through the openings is all located inside the GTV target. The design of the virtual TOMOGRID templates can be adjusted or designed such that the cylindrical dose distribution and the high dose volumes are all contained within the TOMOGRID target ( Figure 7B ). Figure 8 shows the GTV target dose volume histograms from P-TPS and HT-TPS. The results show that the areas-underthe-curve is comparable between the two plans.
The doses to the GRID target and to the OARs for both P-TPS and HT-TPS plans are shown in Table I . The valley to peak dose ratio is also calculated to evaluate the heterogeneity of the dose distribution within the GTV target. Table I shows that the mean dose to the GTV target and the valley to peak dose ratio are very similar between the Pinnacle and HT (TOMOGRID template 1) treatment plans. For the HT-TPS plan using TOMOGRID template 2, the mean GTV target dose and the valley to peak ratio are both higher as compared to the other two plans. The maximum doses to the normal tissue and to the lung are also reduced in the HT-TPS plans as compared to the P-TPS plan. 
Patient Specific Quality Assurance with HT-GRID
The patient specific quality assurance for HT-GRID was performed. The results show that the gamma agreement index score was 98.4% (3%, 3 mm). The dose percentage difference at the isocenter for point dose verification between the calculation and measurement was 2.87%. These results show a good agreement between the planned and the delivered doses.
Discussion and Conclusion
This dosimetric comparison study of GRID therapy using commercially available collimator versus novel virtual TOMOGRID template was performed by investigating the dose profiles delivered by LINAC-GRID and HT-GRID. The results showed that by choosing a properly designed TOMOGRID template, HT can deliver a comparable dose distribution to that of LINAC-GRID treatment.
The commercially available GRID block is a universal GRID block for all patients and used as an accessory to obtain a GRID dose distribution in the patient with limited ability to customize GRID plans. For LINAC-GRID typically using single static field, the dose to the target decreased rapidly with depth and the maximum dose can be located at a shallow depth and outside the GTV target.
For the HT-GRID therapy, the virtual TOMOGRID template is a patient specific designed template. The number of openings, center-to-center distances, and the opening distribution within the GTV target can be customized. The design of the TOMOGRID template will depend on the tumor size, the tumor shape, its depth, and OARs in proximity and the diameter of the openings and their center-to-center distance. The dose profile at certain depth and the dose heterogeneity (valley to peak dose ratio) also vary depending on the virtual TOMOGRID template used. This study showed that HT-TPS plan had a larger valley to peak dose ratio compared to the P-TPS plan (0.2 for the Pinnacle plan and 0.5 and 0.42 for HT plans) for solid water phantom study whereas the same valley to peak dose ratio was obtained (0.005 from P-TPS plan and 0.006 from HT-TPS plan) for the real patient plan. This difference between phantom and patient plans is because the solid water phantom was used initially to test the capability of delivering a typical GRID therapy dose distribution using the HT unit and to investigate the beam characteristics under both the LINAC-GRID and HT-GRID. No attempt was made to optimize the center-to-center distance or opening diameter. Thus, the valley to peak dose ratio for the solid water phantom plan was higher as compared to that of the real patient plans. For the variation of the results between the two virtual TOMOGRID templates, it shows that the design of the virtual TOMOGRID template directly affects the delivered dose to the GTV target and the OARs around the GTV target. So careful customization of virtual TOMOGRID template is critical to achieving the most suitable dose distribution for the HT-GRID treatment.
The doses to OARs were calculated and compared between P-TPS and HT-TPS showing similar mean dose and DVH of GTV target. The doses to OARs using HT were reduced as compared to those calculated from P-TPS (Table I ). In HT-GRID, the maximum dose to the nearby normal tissue was 13.59 Gy from P-TPS plan whereas the maximum dose to normal tissue was reduced to 5.68 Gy and 6.17 Gy from HT-TPS plans which was 120% lower as compared to the P-TPS plan.
The maximum dose to the lung was 15.07 Gy from P-TPS plan and was 10.41 Gy and 10.28 Gy from HT-TPS plans which was 31% lower than the P-TPS plan. These could be explained by the following reasons. First, HT-GRID delivers intensity modulated radiation therapy (IMRT). In IMRT treatment planning used in HT-TPS, there is better control of the dose deposition within the GTV target and more sparing of the surrounding normal tissues with consistent location of the maximum dose within the GTV target in contradiction to the LINAC-GRID plan. Second, LINAC-GRID treatment plans may need to use 18 MV X-ray beams to cover deep seated GTV targets. All HT-GRID plans only use 6 MV X-ray beam to treat the patients. This higher X-ray energy used in LINAC-GRID will contribute higher dose to the OARs. Third, LINAC-GRID uses a single static field to treat the tumor. The dose fall-off depends on the energy of the X-ray beam and cannot be customized to fit the irregular shape of the tumor. X-ray beam can, therefore, traverse an organ-at-risk (OAR) before reaching the intended target ( Figure 6A ) and after passing through the target leading to an increase in the OAR dose. In HT-GRID therapy, the multiple beam projections, the use of beam intensity modulations, and the use of the virtual TOMOGRID template can customized the dose distribution in three-dimensional space to better conform to the shape of the GTV target. All these are not possible with LINAC-GRID.
Although the average normal tissue dose was very low (less than 1 Gy from both the P-TPS plan and the HT-TPS plan), the average normal tissue dose calculated from HT-TPS plans was higher than the dose calculated from the P-TPS plan (Table I) . This might due to the nature of the helical beam in HT unit. HT can deliver a higher integral dose to the normal tissue as compared to LINAC-GRID (8) . In this study, we did not try to reduce the average normal tissue dose during the optimization process. The focus of our study is in shaping the dose distribution to better conform to the target and avoiding the location of maximum dose in normal tissues. We accomplish both goals.
Although, several clinical publications are available for GRID therapy, its radiobiology is incompletely understood. Plausible mechanisms of how GRID therapy exerts an effect at a cellular level have been explained by the induction of tumor necrosis factor-a and ceramide, and by down regulation of transforming growth factor-b1 (9) . In addition, GRID therapy has broad systemic effects leading to an increase in a variety of cytokines, which correlate with clinical outcome (10) . It is thought that cells exposed to a high dose of radiation release these cytokines that may influence the un-irradiated cell through the "by stander effect". We have recently established in pre-clinical models that substantial bystander killing occurs when GRID therapy is applied to tumor cells in culture (11, 12) . These effects may be involved with the improved tumor control and outcomes that have been observed in several clinical studies involving GRID therapy (13) (14) (15) .
HT-GRID can provide equivalent or better treatment plans as compared to the LINAC-GRID. It also allows 3-D optimization to achieve superior sparing of OAR and no high-dose spill outside the GRID GTV as compared to LINAC-GRID. Our future work will include advance studies to generate deliverable GRID patient treatment plans and eventually to routinely use GRID HT in clinical settings.
